Pd 0332991

Phase 3Small molecule

Pfizer

Pd 0332991 is one of 277 small molecule programs targeting Metastatic Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

276

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

Liver CancerActive, not recruiting

Breast CancerActive, not recruiting

GlioblastomaActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Gastrointestinal Stromal TumorActive, not recruiting

Acute LeukemiaActive, not recruiting

Metastatic MelanomaPhase 1/Phase 2

Active, not recruiting

Liver CancerPhase 2

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Mantle Cell LymphomaPhase 1

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Gastrointestinal Stromal TumorPhase 2

Active, not recruiting

Acute LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Pd 0332991

Pfizer

Phase 3

3 2

Trodelvy

Gilead

Preclinical

37 3

Tecentriq

Roche

Preclinical

36 4

Avastin

BBio-Thera Solutions

Preclinical

153 5

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

Voltaren

Novartis

Preclinical

1 8

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 9

Tricor

JJagotec

Preclinical

1 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer3 trials

A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT01684215·61 enrolled

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00721409·177 enrolled

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Completed· Pfizer logo

Pfizer·Phase 3·NCT01740427·666 enrolled

Mantle Cell Lymphoma2 trials

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Terminated·WWeill Medical College of Cornell University·Phase 1·NCT01111188·20 enrolled

An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

Completed· Pfizer logo

Pfizer·Phase 1·NCT00420056·17 enrolled

Phase II1 trial

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Completed·—·Phase 2·NCT01037790·304 enrolled

Metastatic Melanoma1 trial

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT02202200·40 enrolled

Advanced Cancer1 trial

A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00141297·74 enrolled

9 more indications

Multiple Myeloma1 trial

An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Completed· Pfizer logo

Pfizer·Phase 2·NCT00555906·53 enrolled

Solid Tumor Malignancies1 trial

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

Unknown status·GGeorgetown University·Phase 1·NCT01522989·37 enrolled

Liver Cancer1 trial

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01356628·23 enrolled

Glioblastoma1 trial

A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma

Terminated·UUniversity of California, San Francisco·Phase 2·NCT01227434·23 enrolled

Squamous Cell Carcinoma1 trial

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Completed·WWashington University School of Medicine·Phase 1/2·NCT02101034·96 enrolled

Gastrointestinal Stromal Tumor1 trial

Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

Completed·IInstitut Bergonié·Phase 2·NCT01907607·29 enrolled

Interaction1 trial

A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.

Completed· Pfizer logo

Pfizer·Phase 1·NCT01756781·26 enrolled

Acute Leukemia1 trial

A Phase I and Pharmacodynamic Trial of Timed Sequential Administration of the Cyclin Dependent Kinase 4/6 Inhibitor PD 0332991 Followed by Cytarabine Plus Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasias

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01701375·2 enrolled

Unspecified1 trial

Relative Bioavailability Study

Completed· Pfizer logo

Pfizer·Phase 1·NCT01602887·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Pd 0332991. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pd 0332991 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pd 0332991. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Pd 0332991

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer3 trials

Mantle Cell Lymphoma2 trials

Phase II1 trial

Metastatic Melanoma1 trial

Advanced Cancer1 trial

Multiple Myeloma1 trial

Solid Tumor Malignancies1 trial

Liver Cancer1 trial

Glioblastoma1 trial

Squamous Cell Carcinoma1 trial

Gastrointestinal Stromal Tumor1 trial

Interaction1 trial

Acute Leukemia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News